Clinical Trial Update: Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating palbociclib plus letrozole in postmenopausal women with HR-positive, HER2-negative advanced breast cancer for whom letrozole is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Advanced Breast Cancer Female | Phase 3 | Status: COMPLETED | Results posted: 2020-05-21